Blum-Tirouvanziam U, Servis C, Habluetzel A, Valmori D, Men Y, Esposito F, Del Nero L, Holmes N, Fasel N, Corradin G
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.
J Immunol. 1995 Apr 15;154(8):3922-31.
Localization of human MHC class I-restricted T cell epitopes in the circumsporozoite (CS) protein of the human parasite Plasmodium falciparum is an important objective in the development of antimalarial vaccines. To this purpose, we synthesized a series of overlapping synthetic 20-mer peptides, spanning the entire sequence of the 7G8 CS molecule except for the central repeat B cell domain. The P.f.CS peptides were first tested for their ability to bind to the human MHC class I HLA-A2.1 molecule on T2, a human cell line. Subsequently, the use of a series of shorter peptide analogues allowed us to determine the optimal A2.1 binding sequence present in several of the 20-mers. Binding P.f.CS peptides were further tested for their capacity to activate PBL from HLA-A2.1+ immune donors living in a malaria-endemic area. Specific IFN-gamma production was detected in the supernatant of cultures of PBL from exposed individuals. Cytotoxic T cell lines and clones were derived from the PBL of one responder, and their activity was shown to be HLA-A2.1-restricted and specific for the peptide 334-342 of the CS protein. In addition, double transgenic HLA-A2.1 x human beta 2-microglobulin mice were immunized with peptide 1-10 of the CS protein. T cells derived from immune lymph nodes displayed a peptide-specific HLA-A2.1-restricted cytolytic activity after one in vitro stimulation.
确定人类疟原虫恶性疟原虫环子孢子蛋白(CS)中人类MHC I类限制性T细胞表位的定位,是抗疟疫苗研发的一个重要目标。为此,我们合成了一系列重叠的20聚体合成肽,覆盖了7G8 CS分子的整个序列,但不包括中央重复B细胞结构域。首先检测恶性疟原虫CS肽与人类细胞系T2上的人类MHC I类HLA - A2.1分子结合的能力。随后,通过使用一系列较短的肽类似物,我们得以确定在多个20聚体中存在的最佳A2.1结合序列。对结合的恶性疟原虫CS肽进一步检测其激活来自生活在疟疾流行地区的HLA - A2.1 +免疫供体的外周血淋巴细胞(PBL)的能力。在来自暴露个体的PBL培养上清液中检测到特异性γ干扰素的产生。从一名应答者的PBL中获得了细胞毒性T细胞系和克隆,其活性显示为HLA - A2.1限制性且对CS蛋白的334 - 342肽段具有特异性。此外,用CS蛋白的1 - 10肽免疫双转基因HLA - A2.1×人β2 -微球蛋白小鼠。来自免疫淋巴结的T细胞在一次体外刺激后表现出肽特异性的HLA - A2.1限制性溶细胞活性。